Watching!
$LSTA.US$ Latest earnings are a win! They have cash enough to fund operations through 2025 as of latest financial reports. Their pipeline has developed nicely. Progress in their lead asset, LSTA1, has been noteworthy. The asset is currently the subject of several planned and active Phase 1b/2a and 2b global clinical studies in various solid tumors. They have made significant advancements in the initiation and progression of new clinical development programs during the last quarter. This progress will bring a steady flow of news throughout 2024. Furthermore, high enrollment levels in key studies such as ASCEND and BOLSTER, along with the expected completion of enrollment in the CENDIFOX and iLSTA trials![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
